News
06-16-2013, 10:12 PM
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
More... (http://www.news-medical.net/news/20130617/Ambrx-ZMC-partner-to-develop-and-commercialize-ARX788-for-treatment-of-Her2-positive-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130617/Ambrx-ZMC-partner-to-develop-and-commercialize-ARX788-for-treatment-of-Her2-positive-breast-cancer.aspx)